EYLEA® (aflibercept) 8 mg
Diabetic macular oedema (DMO)
CONFIDENCE IN YOUR CHOICE WITH EYLEA® (aflibercept) 8 mg
Give your eligible
- Mean CRT reductions in the EYLEA 8 mg 8q12 and 8q16 arms (PHOTON) were −128.7 µm and −127.0 µm 4 weeks after 1 dose and reduction was maintained through Weeks 96–156.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).
- Lasting vision gains through Week 156
- As few as 10 injections over 3 years
- CRT reduction was observed 4 weeks after the first loading dose with EYLEA 8 mg
- Drying effect sustained through Week 156
- In a post‑hoc analysis of patients with the highest baseline CRT, EYLEA 8 mg demonstrated more durable drying with fewer injections vs EYLEA 2 mg (PHOTON)*
- ~5 in 10 patients last assigned to ≥Q20 at Week 156
- Patients with stable visual and/or anatomic outcomes can maintain or extend previous treatment intervals after the first injection of EYLEA 8 mg†
- Patients with suboptimal visual and/or anatomic outcomes may start with 1 injection per month of EYLEA 8 mg for up to 3 consecutive doses‡
*This data is from a PHOTON post hoc analysis and results should be interpreted with this limitation in mind. Numerically less fluid reaccumulation was observed with EYLEA 8 mg versus EYLEA 2 mg among eyes in CRT Q4 (Q4 baseline CRT: >528 µm). EYLEA 8Q12 and 8Q16 groups demonstrated lower CRT increases (with 3 loading doses) than the EYLEA 2Q8 group (with 5 loading doses).
†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. For patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products and are switching to EYLEA 8 mg, the treatment regimen can differ from that used for treatment-naïve patients. Treatment intervals should be determined based on visual and/or anatomic outcomes: in patients with stable visual and/or anatomic outcomes, previous treatment intervals can be maintained or extended after the first injection of EYLEA 114.3 mg/mL, such as with a T&E dosing regimen; in patients with suboptimal visual and/or anatomic outcomes, treatment with EYLEA 8 mg may begin with 1 injection per month for up to 3 consecutive doses followed by adjustment of injection intervals, such as with a T&E dosing regimen. Consult the SmPC for full posology.
‡Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.
In this
Prescribing information for EYLEA® (aflibercept)
PHOTON
Optimise vision whilst minimising burden
In PHOTON, lasting BCVA gains from baseline were non-inferior with EYLEA 8 mg vs EYLEA 2 mg and maintained through Week 156, with as few as 10 injections over 3 years*
*eFAS, observed cases.
Extend treatment intervals for eligible patients in your DMO clinic
At Week 156, >8 out of 10 patients in the EYLEA 2Q8→8 mg group achieved a last completed dosing interval of ≥Q12 at Week 156, within a year of switching (PHOTON)*
Could having more patients reach longer intervals help streamline your clinic?
*Patients completing Week 156: 8Q12/8Q16 n=152; 2Q8→8 mg n=58.
At Week 156, ~5 in 10 patients were last assigned to ≥Q20 in the EYLEA 8Q12/8Q16 group*
*Patients who were randomised to the 8Q12 or 8Q16 groups at the beginning of the PHOTON study and continued treatment with EYLEA 8 mg through the PHOTON extension study.
†eFAS, patients completing Week 156.
2Q8, 2 mg every 8 weeks; 8Q12, 8 mg every 12 weeks; 8Q16, 8 mg every 16 weeks; AE, adverse event; APTC, Anti-Platelet Trialists’ Collaboration; BCVA, best-corrected visual acuity; CRT, central retinal thickness; DMO, diabetic macular oedema; DRM, dosing regimen modification; eFAS, extension phase full analysis set; eSAF, extension safety analysis set; ETDRS, Early Treatment of Diabetic Retinopathy Study; FAS, full analysis set; IOI, intraocular inflammation; IOP, intraocular pressure; nAMD, neovascular (wet) age-related macular degeneration; Q4, every 4 weeks; Q8, every 8 weeks; Q12, every 12 weeks; Q16, every 16 weeks; Q20, every 20 weeks; Q24, every 24 weeks; SAE, serious adverse event; SAF, safety analysis set; SD, standard deviation; SmPC, Summary of Product Characteristics; T&E, treat and extend; TEAE, treatment-emergent adverse event; VEGF, vascular endothelial growth factor.
PP-EYL-GB-3108 | March 2026